Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Immunotherapy for TNBC

June 23rd 2016

Is There a Role for TNBC Subtyping?

June 23rd 2016

Biosimilar Trastuzumab in HER2-Positive Breast Cancer

June 23rd 2016

Neratinib and HER2 Activating Mutations in Breast Cancer

June 23rd 2016

Patient Selection for Neratinib in Metastatic Breast Cancer

June 23rd 2016

The Emerging Role of Neratinib in HER2+ MBC

June 23rd 2016

PHEREXA Trial in HER2+ Disease

June 23rd 2016

Adjuvant TDM-1 and the KRISTINE Trial

June 23rd 2016

What is New for HER2 MBC?

June 23rd 2016

The Emerging Role of PI3K Inhibition in Breast Cancer

June 23rd 2016

The Ongoing Role of Everolimus in ER-Positive MBC

June 23rd 2016

FDA Breakthrough Status for Abemaciclib

June 23rd 2016

CDK4/6 Inhibitors in Hormone Receptor-Driven MBC

June 23rd 2016

ESR Mutations and Resistance to Endocrine Therapy in Breast Cancer

June 23rd 2016

Neoadjuvant HER2+ Breast Cancer Options Need Refinement, Expert Says

June 22nd 2016

Lisa A. Carey, MD, comments on the recent I-SPY 2 and KRISTINE findings, the I-SPY 2 program as a whole, and the work ahead in the neoadjuvant landscape of HER2-positive breast cancer.

Breast Cancer Milestones Are Unfolding on Several Fronts

June 20th 2016

During the past 2 years, there have been a number of advancements in the treatment of metastatic breast cancer that include the development of novel agents and new strategies in several disease settings, resulting in improved outcomes for patients.

Biosimilar Era Gets Rolling in Oncology

June 17th 2016

After years of anticipation, biosimilar versions of the most widely administered monoclonal antibodies in oncology care are moving closer to fruition for the US market, starting with a new form of trastuzumab (Herceptin).

Dr. Dickler on MONARCH 1 Results in HR+/HER2- Breast Cancer

June 7th 2016

Maura N. Dickler, MD, Memorial Sloan Kettering Cancer Center, discusses the results of the single-arm MONARCH 1 trial, which examined the efficacy of the CDK4/6 inhibitor abemaciclib in heavily pretreated patients with refractory, hormone-receptor (HR)–positive, HER2-negative advanced breast cancer.

Impressive Upfront Palbociclib PFS Benefit Confirmed in ER+/HER2- Breast Cancer

June 7th 2016

Adding the CDK 4/6 inhibitor palbociclib (Ibrance) to letrozole reduced the risk of disease progression by 42% compared with letrozole alone in patients with ER-positive, HER2-negative advanced or metastatic breast cancer.

Black Women Who Are BRCA Carriers Less Likely to Pursue Breast and Ovarian Cancer Risk Reduction

June 7th 2016

Young black women with breast cancer are much less likely to have BRCA testing or, if they carry a BRCA mutation, to undergo risk-reducing prophylactic mastectomy or salpingo-oophorectomy.